#USA #New York #Levi & Korsinsky #Aardvark Therapeutics #AARD class action

Alert for Aardvark Therapeutics Investors

As the October 13, 2026 deadline approaches, investors who have suffered financial losses due to Aardvark Therapeutics, Inc. (NASDAQ: AARD) are urged to take action. SueWallSt, representing the legal firm Levi & Korsinsky LLP, is reminding shareholders of their rights in light of recent developments regarding the company's stock performance.

In February 2025, Aardvark Therapeutics debuted on the NASDAQ with an initial public offering (IPO) priced at $16.00 per share. The company successfully raised over $87 million, attracting considerable investor interest. However, the journey swiftly took a downturn. By May 2026, shares plummeted to $4.57 following alarming news of a voluntary pause on its Phase 3 HERO clinical trial and a subsequent FDA clinical hold. This drastic decline in stock value, representing a staggering loss of over $11 from the IPO price, has sparked significant concern among investors.

Timeline of Key Events

To better understand the situation surrounding Aardvark Therapeutics, let’s review the timeline of critical events that impacted the company and its shareholders:
1. February 13, 2025: Aardvark announces its successful IPO, claiming that its drug ARD-101 was relatively safe with minimal systemic exposure.
2. March 31, 2025: In its annual report, the company maintains that ARD-101 has limited systemic absorption, reinforcing its safety claims.
3. November 13, 2025: Subsequent quarterly filings continue to describe ARD-101 as well-tolerated based on previous Phase 2 trials.
4. February 27, 2026: Aardvark halts the HERO trial due to safety concerns arising from reversible cardiac observations, which marks a critical turning point for investor sentiment.
5. May 14, 2026: The FDA places a full clinical hold on the IND for ARD-101, leading to a drastic drop in stock price after the announcement.

Why These Events Matter to Shareholders

The crux of the securities class action lies in allegations that Aardvark Therapeutics misrepresented the safety and efficacy of its drug ARD-101. Despite the company’s repeated assurances about the drug, the reality turned grim as it faced serious regulatory scrutiny. According to the pleading, investors were led to believe that the drug was safe when, in fact, issues were emerging that were not disclosed until much later, significantly harming the stock's value.

What Investors Should Know

For investors who purchased Aardvark securities between February 13, 2025, and May 14, 2026, this is a pivotal time to ascertain whether they qualify for compensation due to the drastic decrease in stock prices. Investors are advised to gather pertinent information, including brokerage records that detail purchase dates and prices.

Moreover, individuals who sold their shares before the announcement but purchased them within the class period could still be eligible to recover losses. Immediate action is not necessary to retain eligibility as an absent class member, which often is a concern for investors unsure about the litigation process.

Getting in Touch

Interested investors are encouraged to contact Joseph E. Levi, Esq. at Levi & Korsinsky LLP for an evaluation of their potential recovery. With years of experience in securities litigation, the firm invites those affected by Aardvark’s stock decline to submit their information for a no-obligation review.

Timely and accurate disclosures are crucial for maintaining investor confidence in the market. This case accentuates the need for transparency, particularly for companies in the clinical stages of drug development. As more developments unfold, affected investors are best positioned by staying informed and taking appropriate action.

For further details on the lawsuit, or to ascertain eligibility for recovery, reach out via email or by phone at (888) SueWallSt.

Act now to safeguard your investment as the deadline approaches, ensuring you do not miss the opportunity for potential financial restitution.